177Lu-OncoFAP-23 is a small molecule radiotracer with ultra high affinity for Fibroblast Activation Protein (FAP), an antigen overexpressed in more than 90% of epithelial cancers. The product consists of (i) a small organic ligand targeting FAP, (ii) an innovative spacer structure and (iii) a DOTAGA chelator for the incorporation of 177Lutetium.

177Lu-OncoFAP-23 displays best-in-class performance both in vitro and in vivo with the highest reported affinity to the FAP antigen. The product has shown a rapid and selective accumulation in the tumor mass in preclinical models of cancer, with an extraordinarily long tumor residence time.

177Lu-OncoFAP-23 has demonstrated a strong anti-tumor efficacy in mouse models of cancer, even at very low doses (5 MBq per mouse). This potent anti-tumor effect was further enhanced when combined with tumor-targeted proinflammatory cytokines (e.g., L19-IL2).

FAP is expressed in more than 90% of epithelial cancers (e.g., malignant breast, colorectal, ovarian, lung, skin, prostate and pancreatic cancers, as well as in some soft tissue and bone sarcomas). Therefore, Philochem is developing 177Lu-OncoFAP-23 for the treatment of various FAP-expressing solid malignancies. A first-in-human trial with 177Lu-OncoFAP-23 alone and in combination with the immunocytokine L19-IL2 is expected to start by early 2024.

  • OncoFAP-68Ga has recently entered in a first-in-man imaging study in patients with advanced solid cancers
  • Additional studies with OncoFAP-68Ga (Imaging) and OncoFAP-177Lu (Therapy) are about to start